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ABSTRACT
Neoadjuvant cisplatin-based combination chemotherapy for
muscle-invasive bladder cancer (MIBC) has been shown to
confer a survival advantage in two randomized clinical trials
and a meta-analysis. Despite level 1 evidence supporting its
benefit, utilization remains dismal with nearly one-half of pa-
tients ineligible for cisplatin-based therapy because of renal
dysfunction, impaired performance status, and/or coexisting
medical problems. This situation highlights the need for the
developmentofnovel therapies for themanagementofMIBC,
a diseasewith a lethal phenotype. The neoadjuvant paradigm
in bladder cancer offers many advantages for accelerated
drugdevelopment. First, there is a greater likelihoodof suc-
cessful therapy at an earlier disease state thatmay be char-
acterized by less genomic instability compared with the
metastatic setting, with an early readout of activity with re-
sults determined inmonths rather than years. Second, pre-
and post-treatment tumor tissue collection in patientswith
MIBC is performed as the standard of carewithout the need
for research-directed biopsies, allowing for the ability to
perform important correlative studies and to monitor tu-
mor response to therapy in “real time.” Third, pathological
complete response (pT0) predicts for improved outcome in
patients with MIBC. Fourth, there is a strong biological ra-
tionale with rapidly accumulating evidence for actionable
targets in bladder cancer. This review focuses on the neo-
adjuvant paradigm for accelerateddrugdevelopmentusing
bladder cancer as the ideal model. The Oncologist 2013;18:
933–940
Implications for Practice: Recent recommendations to use the neoadjuvant setting in breast cancer as an accelerated drug de-
velopment pathway make a similar approach in bladder cancer very appealing. The current article will review the rationale for
consideration of bladder cancer as the ideal neoadjuvantmodel for accelerated drug development. Several factors including the
easeof bladder tumor tissue collectionperformedas standardof care, theuseof pathologic response as an intermediatemarker
for overall outcome, and a richer understanding of the important molecular pathways involved in bladder cancer development
andprogressionmake theneoadjuvant paradigmparticularly relevant. The ability to conduct clinical trials that require fewer pa-
tients and efficiently explore disease biology will undoubtedly lead to the development of novel therapies and have a profound
effect on every daymedical practice.
INTRODUCTION
TheNationalCancer Institute (NCI) clinical trialsdesigntask force
statement supports trial designs that improve efficiency and
shorten development time [1]. Overall survival (OS) remains the
gold standardandthemostdependableendpoint in cancer clini-
cal trials to support drug approval by theU.S. FoodandDrugAd-
ministration (FDA); however, surrogate endpoints, such as
disease-free survival (DFS), are also acceptable for accelerated
approval with a sponsor commitment to provide confirmatory
evidenceinsubsequenttrials[2].OSisprecise,freefrombias,and
easy to measure, yet it requires randomized controlled studies
with large patient populations for adequate power andmay be
difficult to achieve with subsequent therapeutic interventions
that affect outcome. From December 11, 1992, to July 1, 2010,
the FDA granted accelerated approval to 35 oncology products
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for 47 new indications [3]. Confirmatory trials were performed
for26of the47newindications, resulting inregularapproval.Ac-
celeratedapprovalofoncologyproductshasresultedintimesav-
ings in terms of earlier availability of drugs for cancer patients
(median time between accelerated approval and regular ap-
proval of oncology products was 3.9 years;mean: 4.7 years) [3].
Anastrozole, for example, was granted accelerated approval on
September 5, 2002, for adjuvant therapy for postmenopausal
hormonereceptor-positivebreastcancerbasedonthesurrogate
endpoint of DFS, with regular approval occurring nearly 3 years
later [4].
The neoadjuvant chemotherapy paradigm is an effective
clinical platform in patients with various solid tumor malig-
nancies [5–8]. In a large breast cancer study (B18) by the Na-
tional Surgical Adjuvant Breast and Bowel Project (NSABP),
1,523 women were randomly assigned to preoperative or
postoperative doxorubicin and cyclophosphamide [9]. The
primary study endpoint included clinical tumor response to
preoperative therapy. Nearly 15 years ago, this study estab-
lished that neoadjuvant chemotherapywas as effective as ad-
juvant chemotherapy, permittedmore lumpectomies in early
stage disease, and simultaneously allowed for further evalua-
tion of breast cancer biology. Tumor response in this setting
correlated with outcome and could serve as a surrogate
marker for chemotherapy effect on micrometastases. Pa-
tient-reported outcomes like health-related quality of life
measures are actively beingpursuedandhave resulted in sev-
eral cancer-drug approvals [10]. Ongoing neoadjuvant che-
motherapy studies in breast cancer, such as the Investigation
of Serial Studies to Predict Your Therapeutic Response with
Imaging andMolecular Analysis 2 (I-SPY2), have evolved from
this NSABPmodel and incorporate the exploitation of action-
able biological targets using histological subtypes as well as
human epidermal growth factor receptor 2 (Her-2) positivity
[11, 12–15]. In a New England Journal of Medicine editorial,
Prowell and Pazdur discuss a bolder step for accelerated drug
development using pathological complete response as a surro-
gate for OS or DFS for accelerated drug approval in early breast
cancer [16]. Much like the neoadjuvant trials in breast cancer,
pathological response after neoadjuvant therapy represents a
marker for outcome in bladder cancer [17]. This review focuses
onbladder canceras the idealmodel forutilizationof theneoad-
juvantparadigmforaccelerateddrugdevelopment.
BLADDER CANCER
In the United States, bladder cancer is a commonmalignancy
withanestimated73,510newcasesand14,880deaths for the
year 2012 [18]. Bladder cancer is predominantly a disease of
older persons with an average age of 73 years. Although the
majority of patients are diagnosed with noninvasive disease,
nearly 20%–30%will progress to the lethal phenotypeofmus-
cle-invasive bladder cancer (MIBC) and approximately 20%–
30% of patients will haveMIBC at the time of initial diagnosis.
Despite an aggressive surgical approach with radical cystec-
tomy (RC) with bilateral pelvic lymph node dissection for
MIBC,50% of these patients will develop recurrent or met-
astatic disease and succumb to complications related to blad-
der cancer. To improve on the poor outcome for many
patients withMIBC, new targeted therapeutics and novel ap-
proaches to drug development are desperately needed.
ADJUVANTTHERAPY INMIBC: POORACCRUAL,
EARLY CLOSURE
Many of the adjuvant chemotherapy trials in bladder cancer
have been problematic and underpowered, and a definitive
survivalbenefithasbeendifficult todemonstrate [19]. Several
trialswereundertakenbutclosedprematurelydue topoorac-
crual. TheEuropeanOrganization forResearchandTreatment
of Cancer’s EORTC30994, for example, a randomizedphase III
trial comparing immediate versus deferred chemotherapy af-
terRC inpatientswithpT3-pT4,and/orNM0transitional cell
carcinoma of the bladder, was closed after 7 years with 278
patients enrolled of a planned 340 patients (ClinicalTrials.gov
identifier NCT00028756).
SOGUG 99/01, the Spanish Oncology Genitourinary
Group-sponsored randomized phase III adjuvant trial using
paclitaxel, cisplatin, andgemcitabine,wasprematurely closed
after 7 years due to poor recruitment and failure to meet its
planned accrual goal of 340 patients [20]. A phase III study
sponsoredby the ItalianNationalResearchCouncil usingadju-
vant cisplatin-gemcitabine versus observation after RC in pa-
tients with high-risk bladder cancer was closed after 6 years
with194patientsofaplannedaccrualof610patients [21].The
study was underpowered to demonstrate a survival differ-
ence in patients receiving four cycles of adjuvant cisplatin-
gemcitabine (p .24; hazard ratio [HR], 1.29; 95%confidence
interval [CI], 0.84–1.99). With the failure of the adjuvant che-
motherapy studies to date, neoadjuvant chemotherapy repre-
sentsanalternativewithmorepromisingdata to support itsuse.
NEOADJUVANTTHERAPY INMIBC: SURVIVAL BENEFIT
U.S. Intergroup Trial
Neoadjuvant cisplatin-based combination chemotherapy for
MIBC has been shown to improve survival in two randomized
clinical trials and a large meta-analysis (Table 1) [22]. Gross-





(%) Survival rate (%)
Survival
benefit
US Intergroup 22 317 M-VAC times 3 plus cystectomy
vs. Cystectomy alone
38 vs. 15 57 (5 yr)a vs. 42 (5 yr)a Yes
International Collaboration
of Trialists 23
976 CMV times 3 plus cystectomy
vs. Cystectomy or radiotherapy
or both
33 vs. 12 55, 50, 43 (3 yr, 5 yr,
7 yr)b vs. 50, 44, 37
(3 yr, 5 yr, 7 yr)b
Yes
ap .06 by a stratified log-rank test.
bp .048; hazard ratio, 0.85 (95% confidence interval, 0.72, 1.00).
Abbreviations: CMV, cisplatin,methotrexate, vinblastine;M-VAC,methotrexate, vinblastine, doxorubicin, cisplatin.





riod inan intergroupstudyfrom126 institutionsaffiliatedwith
the Southwest Oncology Group (SWOG), the Eastern Cooper-
ative Oncology Group (ECOG), and Cancer and Leukemia
Group B [22]. The patients were randomly assigned to RC
alone or to three cycles ofmethotrexate, vinblastine, doxoru-
bicin, and cisplatin (M-VAC) followed by RC. Median survival
among patients assigned to surgery alone was 46 months,
comparedwith77months amongpatients assigned to combi-
nation therapy (unstratified: p  .05; stratified according to
ageandtumorgrade:p .06). Thepvaluestratifiedaccording
to age and tumor grade of .06 remains valid in the context of
the other supporting data and based on a one-sided trial de-
sign that tested the hypothesis that patients improved with
M-VAConly. Inbothgroups, improvedsurvivalwasassociated
with pathological complete response (pT0). More patients in
thegroup thathadneoadjuvantM-VAC followedbyRC than in
theRC-alone groupachievedpT0 (38%vs. 15%;p .001), and
those achieving pT0 had an 85% 5-year survival rate.
International Collaboration of Trialists Trial
A larger international phase III randomized trial supports the
results seen in the U.S. Intergroup trial [23]. This trial investi-
gated the use of neoadjuvant cisplatin, methotrexate, and
vinblastine (CMV) chemotherapy in MIBC treated with
cystectomy and/or radiotherapy. In total, 976 patients were
enrolled from 106 institutions in 20 countries by seven differ-
ent national or international clinical groups. Patients were
randomly assigned to receive neoadjuvant CMV versus no
CMV.NeoadjuvantCMVprior to cystectomy, radiotherapy, or
both resulted in a 16% reduction in the risk of death (HR, 0.84;
95%CI, 0.72–0.99;p .037), equivalent to increases in3-year
survival from50%to56%, in10-yearsurvival from30%to36%,
and inmediansurvival timeof7months (from37months to44
months). The pT0 rate in patients receiving chemotherapy
was 33%, compared with 12% among those undergoing cys-
tectomy, radiation, or bothwithout chemotherapy [24].
AdvancedBladderCancerMeta-Analysis
Collaboration
Updated results from the Advanced Bladder Cancer Meta-
analysisCollaborationonneoadjuvantchemotherapy in3,005
patients with MIBC treated in 11 randomized clinical trials
demonstrated a significant survival benefit associated with
platinum-based combination chemotherapy (HR, 0.86; 95%
CI, 0.77–0.95; p .003) [25]. This translates to a benefit in OS
from45%to50%,equivalent toa5%absolute improvement in
survival at 5 years. This benefit was consistent across all pa-
tient subgroups. There was also a significant DFS benefit (HR,
0.78; 95% CI, 0.71–0.86; p  .0001), which is equivalent to a
9% absolute improvement at 5 years.
NEOADJUVANTTHERAPY INMIBC:M-VACOR
GEMCITABINE AND CISPLATIN?
In the study of patientswithmetastatic bladder cancer by von
derMaaseetal. , thecombinationofgemcitabineandcisplatin
(GC) was shown to be similar in efficacy to M-VAC, with less
toxicity associated with the GC doublet [26]. Neoadjuvant
chemotherapy with GC has also been evaluated in two retro-
spective analyses with endpoints including pathologic
response and response rate. Dash et al. retrospectively evalu-




staging, chemotherapy delivery, and DFS. In 39 patients who
completed four cycles of neoadjuvant GC, the proportion of
patientswith no residualmuscle-invasive disease (lower than
pT2)was 36%; in the 54M-VAC-treated patients, the ratewas
35%. All 15 patients who received neoadjuvant GC who
achieved a category lower than pT2 remained disease-free at
themedian follow-up of 30months. The pT0 rates for the GC-
andM-VAC-treatedpatientswere 26%and28%, respectively.
The results from a retrospective study by Fairey et al. are
consistent with the MSKCC experience [28]. The study ana-
lyzed 116patientswithMIBC, 58 in the neoadjuvantGC group
and 58 in the neoadjuvantM-VAC group. The outcomesmea-
sured were complete response rate (CRR; pT0N0), partial re-
sponse rate (PRR; pTaN0, pT1N0, or pTisN0), overallmortality
(OM), and recurrence. There was no statistically significant
differencebetween theGCandM-VACgroups in termsof CRR
(27.3%vs.17.1%;p .419)orPRR (45.5%vs.37.1%;p .498).
In addition, there was no difference between the predicted
5-year rates of freedom from OM (p  .634) and recurrence
(p .891). Amajor limitation of both studies is the retrospec-
tive study design, thus we are unable to definitively conclude
that GC andM-VAC are equivalent in this setting. Phase II clin-
ical trials evaluatingdose-denseGCasneoadjuvant therapy in
MIBC (ClinicalTrials.gov identifier NCT01589094) and in pa-
tients with high-grade upper tract urothelial carcinoma (UC;
ClinicalTrials.gov identifier NCT0126178) are ongoing.
Unlike Fairey et al. and the MSKCC experience with GC,
Weight et al. [29] performed a retrospective study that dem-
onstrated a lack of pathological downstaging with neoadju-
vant chemotherapy for MIBC. This group evaluated 117
patients who underwent open RC at the Cleveland Clinic for
MIBC (T2-T4a, N0–2, M0) from January 2006 to November
2007. They found that of the 29 patients (25%) who received
neoadjuvant chemotherapy (20 patients received GC, 4 re-
ceivedM-VAC,and5receivedother regimens), only2patients
(7%) achieved pT0. Eighteen patients (62%) had non-organ-
confined residual cancer consistent with disease progression
and overall median progression-free survival (PFS) of 10.5
months. The median time interval from date of diagnosis of
MIBC to RCwas 208 days in those patients receiving neoadju-
vant chemotherapy versus 48 days for the immediate RC co-
horts. Possible reasons for these poor outcomes in the study
by Weight et al. include selection bias, with more aggressive
disease selected for the neoadjuvant cohort combinedwith use
Despite level 1 evidence supporting a survival benefit
for cisplatin-based combination therapy, the utiliza-
tion of neoadjuvant chemotherapy is dismal. The rea-
sons for underutilization are many and include patient
preference andphysician bias aswell as difficulty in the
administration of cisplatin-based chemotherapy to an
older patient population with coexisting medical
problems.
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of non-M-VAC regimens, and/or substantial delay in performing
RC (in the study by Grossman et al. [22], date of diagnosis to RC
was115days).Takentogether,althoughGCappearstohavesim-
ilar efficacy and less toxicity compared withM-VAC, making GC
an attractive alternative in the neoadjuvant setting, a random-
ized prospective trial comparing neoadjuvant GC andM-VAC is
neededbut isunlikely tobeperformed.Acomparative trialofGC
andM-VAC isunlikely tooccurdue to thedifficult accrual seen in
modern perioperative chemotherapy trials in patients with
MIBC.
UNDERUTILIZATION OFNEOADJUVANTTHERAPY INMIBC
Despite level 1 evidence supporting a survival benefit for cis-
platin-based combination therapy, the utilization of neoadju-
vant chemotherapy is dismal [30–34]. The reasons for
underutilization aremany and includepatient preference and
physician bias as well as difficulty in the administration of cis-
platin-based chemotherapy to an older patient population
with coexistingmedical problems [30, 35]. A retrospective re-
view of 238 patients (145 patients with preoperative clinical
stageT2orhigher)whounderwentRCforMIBCbetween2003
and 2008 found that only 17% (25 of 145) of patients who un-
derwent RC for bladder cancer received cisplatin-based neo-
adjuvant chemotherapy. Renal function was adequate
(creatinine clearance [CrCl] 60 ml per minute) for neoadju-
vant cisplatin-based chemotherapy in 67% of the MIBC pa-
tients. Patientswhoreceivedneoadjuvant chemotherapyhad
higher pT0 rates (29% vs. 8%) compared with those who did
not receiveneoadjuvant chemotherapy [36]. Theauthors sug-
gest that in addition to an older patient populationwith coex-
isting medical problems, concerns related to toxicity and the
modest nature of the benefit from neoadjuvant chemother-
apymight explain the underutilization.
INELIGIBILITY FORNEOADJUVANT CISPLATIN-BASED
THERAPY INMIBC
Although the underutilization of neoadjuvant chemotherapy
is amajor problem,manyolder patients are unfit for cisplatin-
based combination treatment for MIBC. In an effort to en-
hance uniformity in clinical trials, Galsky et al. published a
consensus definition of patients unfit for cisplatin based on at
least one of the following criteria: ECOG performance status
of2,CrCl60mLperminute,grade2hearing loss, grade2
neuropathy, and/or New York Heart Association class 3 heart
failure [37].Manycenterswill treatpatientswithaglomerular
filtration rate (GFR) 50 or 55 mL per minute. Furthermore,
the clinician may also consider alternative individual patient
factors on a case-by-case basis for cisplatin treatment deter-
mination, as there are not absolute guidelines regarding cis-
platin eligibility.
To ascertain the prevalence of hearing loss in an increas-
ingly aging U.S. population, Agrawal et al. performed a na-
tional cross-sectional surveywithaudiometric testing in5,742
U.S. adults aged 20–69 years from 1999 to 2004 [38]. They
found that in 2003–2004, 16.1%ofU.S. adults (29million) had
speech-frequency hearing loss. In addition, hearing loss oc-
curredearlier in participantswith smoking and cardiovascular
disease. Individuals diagnosed with bladder cancer are likely
to have increased baseline hearing loss not only due to their
advanced age at diagnosis but also based on smoking history
aswell as possible cardiovascular disease. Inzitari et al. sought
to examine predictors of motor-performance decline by per-
forming a longitudinal review in 1,052 persons ranging from
65 to 84 years old who performed normally at baseline [39].
They found 166 patients had motor-performance decline at
3-year follow-up. Distal symmetrical neuropathywas significant
among several factors associated with motor-performance de-
cline. Baseline distal symmetrical neuropathy is an important
consideration with the use of cisplatin-based chemotherapy to
prevent motor-performance decline, which is associated with
disability, institutionalization,anddeath.Baselinedistalsymmet-
ricalneuropathyand/orhearing loss furtherreduceanolderper-
son’s eligibility for cisplatin-basedchemotherapy.
The vast majority of MIBC patients are unfit for neoadju-
vant cisplatin-based therapy secondary to renal insufficiency.
Dashetal. completeda retrospective review in theMSKCCDe-
partment of Urology RC database in patients who underwent
RC forbladdercancerwithcategorypT3orhigheroranynode-
positive disease between January 1990 andMarch 2005 [40].
Serumcreatinine (SCr)wasmeasuredbefore andafter cystec-
tomy using GFRwith formulas by Cockroft-Gault (CG), Jelliffe,
andtheModificationofDiet inRenalDisease.UsingtheCGfor-
mula, theoverall proportionofpatients ineligible for adjuvant
cisplatin-based chemotherapy was 28%, and 40% of pa-
tients whowere70 years oldwere ineligible.
In a separate study of 194 patients who underwent RC for
MIBC, SCr immediately before andnadir SCr 1–3months after
surgerywereused tocalculateCrCl andGFR [41].A cutoff ofCrCl
60mLperminute orGFR60mLperminute per 1.73m2was
usedtodetermineeligibilityforchemotherapy.Nearly40%ofpa-
tients were ineligible for cisplatin-based neoadjuvant chemo-
therapy due to poor renal function. Furthermore, RC did not
affect eligibility for chemotherapybasedon renal function.
To meet the challenges presented by elderly MIBC pa-
tientswithrenal insufficiency,Hussainetal. completedasmall
study in 23 patients who received GC therapy with the cispla-
tincomponentsplitdosed(35mg/m2)ondays1and8every21
days for a maximum of four cycles [42]. Although limited to a
small numberofpatients, they found that split-dosedGCther-
apy was well tolerated and effective in MIBC patients with a
GFR 40 mL per minute using the CG formula. These studies
highlight thedifficultywithcisplatin-based therapy inpatients
with MIBC and the need for the development of novel thera-
pies with improved tolerability.
THE CASE FORBLADDER CANCER: AN IDEALMODEL FOR
THENEOADJUVANTPARADIGMTOACCELERATE
DRUGDEVELOPMENT
Potential Ethical and Clinical Implications
Neoadjuvant trials in MIBC patients with a high risk of recur-
rence and associatedmortality that exploit actionablemolec-
ular targets are both ethically and clinically warranted. The
I-SPY2 breast cancer trial [11], a study endorsed by the FDA
and institutional review boards across 20 different sites
along with individual sponsors and researchers, was deter-
mined tobeethical in itsdesign for the treatmentof locally ad-
vanced breast cancer in the neoadjuvant setting. In this trial,
all patients who were enrolled were given the current stan-
dard of care and assigned to receive an investigational drug
based on the breast cancer patient’s individual tumor biology




and/or biomarkers. Unlike the I-SPY2model, the bladder can-
cer neoadjuvant model includes potential candidates with
multiple comorbidities often deemed “unfit” for cisplatin-
based chemotherapy. Consequently, novel investigational
agentsmaynotalwaysbeable tobe testedwithabackboneof
cisplatin-based therapy. There is a pressing need for alterna-
tive treatment options in this setting for patientswithbladder
cancer.Clinical implicationssuchas riskofdiseaseprogression
due to treatment delay, ineffectiveness, or side effects must
be weighed against the potential gains in tumor downstaging
and other outcome measures including survival. Short-win-
dow trials of investigational agents with pre- and post-treat-
ment tumor tissue analysis may set the stage for trials with
longer treatment times prior to definitivemanagement.
Using pT0 as aMarker for Overall Outcome
Given the NCI-mandate to support trial designs that improve
efficiency and shorten development time coupled with the
demonstratedefficacyofneoadjuvant therapy inbladdercan-
cer and association with pT0, the neoadjuvant paradigm for
accelerateddrugdevelopment inbladder cancermustbepur-
sued. Studieshave found thatpT0 is associatedwith improved
outcome inMIBCpatients treatedwithneoadjuvant cisplatin-
basedchemotherapy [17,22,23]andsuggest that itmayserve
as an optimal endpoint. The 5-year survival rate for patients
achievingpT0withneoadjuvantM-VAC is 85% [23]. Sonpavde
et al. completed a retrospective study of patients who re-
ceived RC alone versus three cycles of neoadjuvant M-VAC
chemotherapy before RC for bladder cancer from the SWOG-
S8710/INT-0080 trial [17]. The studyevaluated thepathologic
response following RC with OS in a subset of patients who re-
ceived neoadjuvant M-VAC and RC with negative margins.
Sixty-eight (44.2%) of the 154patientswho received neoadju-
vantM-VAChadapathological response lowerthanP2(P0,Pa,
P1, or carcinoma in situ) at RC; 46 patients (29.9%) were P0,
andtheremainderhadP2diseaseorhigherordidnotundergo
RC. Neoadjuvant chemotherapy plus RC with negative mar-
gins with pT0 and lymph node-negative disease correlated
with improvedOS.Despite thesedata,which strongly support
pT0 as a marker for overall outcome in the neoadjuvant
setting with standard chemotherapy, clinical trials will be
needed to determine whether this is the case for newmolec-
ularly targeted therapies. Furthermore, pT0 is not currently a
true surrogate for survival; therefore, PFS and OS are impor-
tant endpoints to include.
The Potential for Less Genomic Instability at an Earlier
Disease State
There may be a greater likelihood of successful therapy at an
earlier disease state that is characterized by less genomic in-
stability compared with the advanced or metastatic setting.
Blaveri et al. studied 98 bladder tumors of diverse stages and
grades by array-based comparative genomic hybridization
(CGH) [43]. Array CGHanalysis showed significant increases in
copynumber alterations andgenomic instabilitywith increas-
ing stage and worse outcome (pTa vs. pT1, p .0003; pTa vs.
pT2-T4, p  .02; pT1 vs. pT2-T4, p  .03). Furthermore, a
worse outcome in muscle-invasive tumors was associated
with the fraction of genomes altered independent of other
clinicopathological parameters.
Pre- and Post-Treatment Tumor Tissue Collection Is
the Standard of Care
Unlike neoadjuvant clinical trials for early breast cancer, pre-
and post-treatment tumor tissue collection in patients with
MIBC is completed as the standard of care (Fig. 1). In addition
to neoadjuvant cisplatin-based combination chemotherapy,
an aggressive surgical approach with RC with bilateral pelvic
lymph node dissection remains the gold standard for surgical
care of MIBC. The RC specimen provides pathological staging
while allowing for important science studies that may be cor-
related with tumor-response assessment. These post-treat-
ment specimens can be compared with pretreatment
specimensobtainedduring the standardof care transurethral
resection of the bladder tumor. In the best-case scenario, the
post-treatment specimenwill result in pT0; however, this lim-
its the ability to perform post-treatment molecular analyses.
Short-window studies to evaluate pre- and post-treatment
samples inMIBCpatientswhoarenot candidates for cisplatin-
based therapiesarewarranted tounderstand theeffecton tu-
mor biology.
THEEVOLVING, STRONG, BIOLOGICAL RATIONALE FOR
TARGETEDTHERAPEUTICS IN BLADDER CANCER
An improved understanding of the biology of bladder cancer
will allow for the design and implementation of trials evaluat-
ing novel agents directed against molecular targets that exist
in patients with muscle-invasive disease. The distinct natural
histories of non-MIBCandMIBCare clearly drivenby their dis-
parate molecular profiles. In contrast to non-MIBC, which is
predominantly characterized by alterations in FGFR3 and
HRAS, MIBC is characterized by loss-of-function mutations in
major tumor suppressor genes including TP53 (also known as
p53), RB1 (also known as RB), and PTEN, leading to an aggres-
sive, lethal phenotype. Thenonoverlappingdistributionof ge-
netic alterationswithin thePIK3CA (also knownas PI3K)-AKT1
(also known as AKT)-mammalian target of rapamycin (mTOR)
pathway, the receptor tyrosine kinase (RTK)-Rat Sarcoma







Standard of Care 
Standard of Care 
Figure 1. Neoadjuvant paradigm in bladder cancer.
Abbreviations: MIBC, muscle-invasive bladder cancer; pCR,
pathological complete response; TURBT, transurethral resection
of the bladder tumor.
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theEGFR (alsoknownasERBB) family suggest that thesealter-
ationsmay represent driver events and thus should be evalu-
ated as potential drug targets.
PI3K-AKT-mTOR Pathway
The PI3K-AKT signal transduction pathway is known to be
aberrantly activated in a number of solid tumors, and a
wide variety of mutations within multiple members of this
pathway have been observed in UC. In select series, muta-
tions of PIK3CA, the gene encoding for the catalytic subunit
of PI3K, have been detected in up to 17% of UC samples
[44]. Deletions and mutations of PTEN, a phosphatase pro-
tein that negatively regulates the activation of PI3K, on
chromosome 10 are documented as occurring in 9% of UC
cases and result in high-grade, invasive UC when combined
with inactivation of p53 in genetically engineered mouse
models [44 – 46]. Activating mutations in AKT in bladder
cancer leads to upregulation of multiple downstream pro-
teins involved in cell-cycle progression and inhibition of ap-
optosis [47]. Activation of the PI3K-AKT-mTOR pathway
correlates with tumor progression and reduced survival in
patients with UC of the bladder [48]. Iyer et al. investigated
the genetic basis of a durable remission in a metastatic
bladder cancer patient treated with everolimus, an mTOR
inhibitor [49].Whole-genome analysis revealed a TSC1mu-
tation in this patient who achieved a durable response
while on everolimus. Subsequent targeted sequencing re-
vealed TSC1 mutations in approximately 8% of 109 addi-
tional bladder cancers evaluated. TSC1 mutations
appeared to correlate with everolimus sensitivity.
This study highlights the importance of tumor tissue




The RAS-MEK-extracellular-signal-regulated kinase (ERK)
signal transduction pathway is also known to have pro-
found effects on proliferative, apoptotic, and differentia-
tion pathways. Deregulated signaling can lead to
unrestrained cellular growth and proliferation, ultimately re-
sulting in tumor formation [50].Anumberofmolecularevents
in invasiveUCactivateMEK/ERKsignaling, includingHRASmu-
tations (10%),mutations of FGFR3 (10%–15%), andmuta-
tions or amplification of ERBB2 [51].
ERBB Family
Targeting EGFR in non-small cell lung cancer patients har-
boring EGFR mutations with drugs like erlotinib and ge-
fitinib have yielded response rates as high as 60% [52, 53].
Cetuximab, a monoclonal antibody inhibitor of EGFR, was
evaluated with or without paclitaxel in a phase II trial in pa-
tients with advanced urothelial tract carcinoma [54].Wong
et al. randomly assigned 39 patients to the single-agent ce-
tuximab armversus the combination arm. Either armwould
close if 7 of the initial 15 patients progressed at the first dis-
ease evaluation at 8 weeks. The single-agent arm closed af-
ter 9 of the 11 patients progressed; however, the
combination arm had an overall response rate of 25%, with
amedian PFS of 16.4weeks and amedianOS of 42weeks. In
a phase II trial, Pruthi et al. evaluated erlotinib, an EGFR ty-
rosine kinase inhibitor in 20 patients with MIBC in the neo-
adjuvant setting. The primary endpoint was pT0 in the RC
specimen. Five patients (25%) were pT0, 7 patients (35%)
were clinically downstaged (pT1 or lower), and 15 (75%)
had organ-confined disease [55].
Hussain et al. investigated the safety and efficacy of tras-
tuzumab, carboplatin, gemcitabine, and paclitaxel (TCGP) in
patientswith advancedUCprospectively evaluated forHer-2/
neu overexpression [56]. Fifty-seven of 109 registered pa-
tients were positive for Her-2/neu (48.6% positive by
immunohistochemistry). Ongoing neoadjuvant clinical trials
incorporatingnovel targetedagents inMIBC includestudiesof
cisplatin, gemcitabine, and sorafenib tosylate (ClinicalTrials.
gov identifier NCT01222676), dasatinib (ClinicalTrials.gov
identifier NCT00706641), lapatinib (ClinicalTrials.gov identi-
fier NCT0124566), and sunitinib (ClinicalTrials.gov identifier
NCT00526656) (Table 2). The gemcitabine, cisplatin, and
sunitinib trial was closed early due to toxicity concerns [57].
The distinct natural histories of non-MIBC and MIBC
are clearly driven by their disparate molecular pro-
files. Incontrast tonon-MIBC,which ispredominantly
characterized by alterations in FGFR3 and HRAS,
MIBC is characterized by loss-of-function mutations
inmajor tumor suppressor genes includingTP53 (also
known as p53), RB1 (also known as RB), and PTEN,
leading to an aggressive, lethal phenotype.
Table 2. Ongoing phase II neoadjuvant targeted therapy trials formuscle-invasive or locally advanced urothelial cancer
Triala Institution No. of patients Regimen Primary endpoint
NCT00585689 University ofMichigan Cancer Center 29 GC plus ABI-007 pCR
NCT00506155 MDACC 60 M-VAC plus Bevacizumab pCR
NCT01222676 Fodazione IRCCS Istituto dei Tumori,Milano 45 GC plus sorafenib tosylate pCR
NCT00706641 Hoosier Oncology Group 25 Dasatinib pCR
NCT01245660 University Hospital, Bordeaux 15 Lapatinib pCR; correlatives
NCT00526656 Case Comprehensive Cancer Center 9 Sunitinib pCR
aClinicalTrials.gov identifier is shown for each trial. AccessedNovember 30, 2012.
Abbreviations: GC, gemcitabine, cisplatin;MDACC,M.D. Anderson Cancer Center;M-VAC,methotrexate, vinblastine, doxorubicin, cisplatin; pCR,
partial complete response.




THENEXT CHALLENGE:MATCHING PATIENTS AND
MOLECULARTARGETS
Basedona report fromtheclinical trial design task forceof the
NCI InvestigationalDrugSteeringCommittee [58], phase I trial
designs canbeoptimized tominimizepatient risksby incorpo-
rating the followingelements: (a)developmentofaccelerated
titration designs that maximize a patient’s chance of being
treated at an active dose; (b) movement beyond safety and
dose selection in phase I trials to identification of target pa-
tientpopulationandpreliminaryevidenceof target inhibition,
especially in the setting ofmolecularly targeted drugs; and (c)
use of phase 0 trials to assess a drug effect on amolecular tar-
get in a small number of patients. An example of a phase I trial
that includedaspecific targetpatientpopulation involvedma-
lignant melanoma patients with the BRAF V600E mutation
that responded to the BRAF inhibitor PLX4032 [59]. Develop-
mentofpredictivebiomarkersmayassist inmatching the indi-
vidual patient with an appropriate molecular target. SWOG,
for example, has sponsored a phase II neoadjuvant trial using
the “CO-eXpression ExtrapolatioN,” or COXEN, algorithm [60,
61], a method of using expression microarray for identifica-
tion of drug sensitivity in vitro followed by comparison to in-
dividual patient tumor gene expression. Based on this
comparison, an optimal therapy would be obtained and
would minimize the patient’s exposure to inert investiga-
tional therapies.
CONCLUSION
Amere 5% of investigational agents tested in phase III cancer
clinical trials ultimately make it to the bedside. It may take a
decade or more for current bladder cancer clinical trials to
lead to paradigm-shifting therapies. To accelerate significant
discoveries at the bench into targeted weapons against blad-
der cancer at the bedside, novel trial designs will need to be
developed. To meet the challenges of future drug develop-
ment in bladder cancer, national experts from the bladder
cancer community convened at a workshop at an NCI confer-
ence entitled “Novel Neoadjuvant Therapy for Bladder
Cancer” to discuss how best tomove the field forward. Explo-
ration of drug targets and therapeutics using the neoadjuvant
setting was one of the key recommendations offered [62].
New therapies are desperately needed for patients with ad-
vanced bladder cancer, and use of the neoadjuvant paradigm
is a promising strategy to accelerate drug development.
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